Page 42 - BRAND BOOK FIXAPROST
P. 42
f LTFC vs fixed combination
Fixed-Dose Combination of Tafluprost and Timolol in the Treatment
of POAG and OHT: Comparison with Other FC Products
Hollo et al. Adv Ther. 2014; 31: 932-44.
LTFC vs Tafluprost/Timolol FC , Travoprost/Timolol FC, Bimatoprost/
Timolol FC
Methodology:
• Litterature review essentially based on the double-masked, controlled
phase III clinical trials with Xalacom , DuoTrav ; Ganfort , and TAF/TIM
®
®
®
Key messages:
• The products yielded a similar reduction in IOP of approximately 32–36%
from an untreated baseline IOP of around 24–29 mmHg.
• Least side effects occurred during treatment with TAF/TIM and Xala-
com . Xalacom contains a very high concentration of BAC (0.02%) and
®
yet causes conjunctival hyperemia on average in only about 3% of the
patients
• LESS OCULAR ADVERSE EVENTS
• LESS HYPERAEMIA
• LESS IRRITATION
f 42
